Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4201MR)

This product GTTS-WQ4201MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4201MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13433MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ2474MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ2930MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ8854MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ1138MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ1949MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ1211MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ5058MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW